Welcome to clinical stage biotech's, all (20 bags+) or nothing, that's why we are here.
Many other sectors you'll sleep better in with a more diversified downside, but retail/major shareholders here typically want that uncapped upside that with the firm diversifying risk away cuts into the return side of the equation which just isn't desirable for allocations in these risky assets.
Distribution for a tiny indication with a tiny level of specialists in the targeted sales pipeline is just silly imo.
DCF Valuation Model for Invex Therapeutics, page-141
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable